文献速递介入腹部DSACTMR

DEB-TACE治疗肝转移性神经内分泌肿瘤的5年单中心临床结局

Clinical Outcomes of DEB-TACE in Hepatic Metastatic Neuroendocrine Tumors: A 5-Year Single-Institutional Experience.
PubMed 文献 · Acad Radiol · 2023-04-25

单中心回顾性队列研究纳入287例肝转移性神经内分泌肿瘤患者,评估DEB-TACE的安全性与疗效。1个月随访mRECIST完全缓解率20.9%、部分缓解率46.3%,主要并发症发生率2.4%,中位无进展生存期14.4个月,1年、3年、5年总生存率分别为80.1%、49.1%、12.3%。结论认为DEB-TACE是可接受的局部区域治疗选择。

要点

  • DEB-TACE治疗后1个月mRECIST评估完全缓解率20.9%、部分缓解率46.3%。
  • 主要并发症发生率仅2.4%,肝功能指标总体稳定。
  • 中位PFS为14.4个月,5年总生存率12.3%。

关键影像表现/征象

  • 90.2%患者为双叶病变,最大肿瘤直径均值4.9±2.8 cm。
  • 14.6%患者无其他器官或淋巴结肿瘤证据。
  • 1个月随访时总胆红素和AST总体稳定,ALT仅升高8.9%(p<0.01)。

诊断标准与关键数值

  • 1个月随访mRECIST评估:完全缓解60例(20.9%),部分缓解133例(46.3%)。
  • 主要并发症发生率2.4%。
  • 总生存率:1年80.1%、3年49.1%、5年12.3%;平均PFS 14.4±12.5个月。

临床应用与阅片要点

  • DEB-TACE可用于不适合或不愿手术的NET肝转移患者,尤其双叶病变者。
  • 术后1个月应行增强影像按mRECIST评估反应以指导后续治疗。
  • 需关注ALT一过性升高,但总体肝功能稳定,严重并发症风险低。

局限性

  • 单中心回顾性设计,存在选择偏倚。
  • 原文未报告无进展生存期和总生存期的多因素分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate single-institution outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of locally advanced neuroendocrine tumor (NET) hepatic metastases with a focus on safety and efficacy of treatment.

MATERIALS AND METHODS: A single-center retrospective cohort study of the outcomes of consecutive patients with NELM who underwent DEB-TACE between 2014 and 2019 was performed. Clinicopathologic characteristics, radiologic response (modified Response Evaluation Criteria in Solid Tumors) at 1-month follow-up, adverse events, progression-free survival (PFS), and overall survival were calculated.

RESULTS: Among 287 patients (mean age of 62 years; 39% male: 61% female), disease burden was bilobar (90.2%) with mean largest tumor diameter measuring 4.9 ± 2.8 cm. Of these patients, 14.6% had no evidence of tumor in other organs or lymph nodes. Complete response occurred in 60 (20.9%) patients while 133 (46.3%) had partial responses. Major complication occurred in 2.4%. Liver function tests including total bilirubin and AST were overall stable at the 1-month follow-up, with only a small increase in the ALT at +8.9% (p < 0.01). Overall survival was 80.1% at 1 year, 49.1% at 3 years, and 12.3% at 5 years with a mean PFS of 14.4 ± 12.5 months.

CONCLUSION: Based on this institutional experience, DEB-TACE is an acceptable locoregional therapy choice for hepatic metastases of NET due to its tolerable safety profile and relative efficacy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Makary, Regalado, Alexander, et al. Clinical Outcomes of DEB-TACE in Hepatic Metastatic Neuroendocrine Tumors: A 5-Year Single-Institutional Experience. Acad Radiol. 2023. PMID: 37105803. doi:10.1016/j.acra.2023.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。